Polyrizon Cash Flow from Financial Activities 2023-2024 | PLRZ

Polyrizon cash flow from financial activities from 2023 to 2024. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities

Polyrizon Cash Flow from Financial Activities 2023-2024 | PLRZ

Polyrizon cash flow from financial activities from 2023 to 2024. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.8B
Amgen (AMGN)$162B
Gilead Sciences (GILD)$140.6B
Vertex Pharmaceuticals (VRTX)$118.3B
Bristol Myers Squibb (BMY)$96.7B
CSL (CSLLY)$85.2B
GSK (GSK)$76.5B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$42.3B
Argenex SE (ARGX)$36.4B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.8B
Insmed (INSM)$19.3B
Biogen (BIIB)$18.9B
Illumina (ILMN)$17.4B
Genmab (GNMSF)$15.2B
Genmab (GMAB)$14.8B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.1B
Exelixis (EXEL)$12.1B
QIAGEN (QGEN)$11.3B
BioMarin Pharmaceutical (BMRN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Legend Biotech (LEGN)$7.6B